All Professionals
Overview
Seo Salimi is a partner and the Co-Head of Equity Capital Markets and Co-Chair of the Corporate Life Science Group of Paul Hastings and is based in the firm's New York office. His practice focuses on representing life science companies and investment banks in public and private capital markets transactions, such as initial public offerings, follow-on offerings, at-the-market transactions, and private placements. Mr. Salimi has extensive experience in cross-border financing transactions, representing issuers and investment banks in complex dual listings and cross border initial public offerings and follow-on offerings. Mr. Salimi is a trusted advisor to both public and private companies in their capital raising strategy and ongoing corporate matters, including SEC compliance and corporate governance.
Mr. Salimi has been recognized as a “Next Generation Partner” for Capital Markets: Equity by The Legal 500 US, where clients note he is “committed, hard-working and driven; his ability to manage across his team, both up and down, as well as his interactions with counsel from the other party makes [Mr. Salimi] invaluable.” In 2020, Mr. Salimi was nominated for the “US Rising Star – Financial & Corporate” award by LMG Life Sciences.
Recognitions
- The Legal 500 US, “Next Generation Partner,” Capital Markets: Equity
- IFLR1000 US, Notable Practitioner, M&A
- LMG Life Sciences, Nominated for “US Rising Star – Financial & Corporate” award (2020)
Education
- University of Southern California Gould School of Law, J.D. (top of class), 2004
- University of California, Irvine, B.A., 2001
Representations
Domestic Representations
- Karuna Therapeutics, Inc. in its initial public offering and follow-on offerings, aggregating over $1.5 billion in proceeds
- HOOKIPA Pharma Inc. in its initial public offering and follow-on offerings, aggregating over $200 million in proceeds
- Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offerings by Arvinas, Inc., aggregating over $600 million in proceeds
- Goldman Sachs & Co. LLC and other underwriters in the $145 million initial public offering by Omega Therapeutics, Inc.
- Goldman Sachs & Co. LLC and the other underwriters in the $145 million initial offering by Harmony Biosciences Holdings, Inc.
- Goldman Sachs & Co. LLC and Morgan Stanley and other underwriters in the $135 million initial public offering by Pandion Therapeutics
- Goldman Sachs & Co. LLC and J.P. Morgan as underwriters in over $1.5 billion of equity offerings by Sarepta Therapeutics, Inc.
- Goldman Sachs & Co. LLC and other underwriters in follow-on public offerings by Syndax Pharmaceuticals, Inc., aggregating over $500 million in proceeds
- BofA Securities, Inc. and Goldman Sachs & Co. LLC in the $350 million PIPE financing by Arvinas, Inc.
- J.P. Morgan Securities and other underwriters in the initial public offering and subsequent PIPE financing by Lexeo Therapeutics, Inc., aggregating over $200 million
- J.P. Morgan Securities and other underwriters in the $75 million follow-on offering by Precigen, Inc.
- TD Cowen in the $150 million PIPE financing by Harpoon Therapeutics, Inc.
- TD Cowen in the $45 million follow on-offering by HumaCyte, Inc.
- Jefferies in the $90 million follow on-offering by Esperion Therapeutics, Inc.
- Leerink Partners in the $80 million follow-on by PepGen Inc.
- Piper Sandler and Raymond James in the $260 million follow-on offering by CymaBay Therapeutics, Inc.
- Piper Sandler and other placement agents in PIPE financings by Skye Biosciences, Inc., aggregating over $90 million
Cross-Border Representations
- CRISPR Therapeutics AG in its initial public offering and follow-on offerings, aggregating over $1.0 billion in proceeds (Country of Issuer: Switzerland)
- Achilles Therapeutics PLC in its $175 million initial public offering (Country of Issuer: United Kingdom)
- Fusion Pharmaceuticals Inc. in its $210 million initial public offering (Country of Issuer: Canada)
- Ablynx NV in its $230 million initial public offering (Country of Issuer: Belgium)
- Goldman Sachs & Co. LLC and other underwriters in the $510 million initial public offering by Exscientia PLC (Country of Issuer: United Kingdom)
- Goldman Sachs & Co. LLC and other underwriters in the $125 million initial public offering by Ambrx, Inc. (Country of Issuer: Cayman Islands)
- Goldman Sachs & Co. LLC and other underwriters in the $107 million initial public offering by Valneva SE (Country of Issuer: France)
- Morgan Stanley, Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offering by Repare Therapeutics Inc., aggregating over $300 million in proceeds (Country of Issuer: Canada)
- Goldman Sachs & Co. LLC, Morgan Stanley and other underwriters in over $500 million of equity offerings by DBV Technologies (Country of Issuer: France)
- Citigroup and other underwriters in the $130 million initial public offering by Opthea Ltd. (Country of Issuer: Australia)
- Leerink Partners in the $140 million public offering by Aurinia Pharmaceuticals Inc. (Country of Issuer: Canada)
Matters may have been completed before joining Paul Hastings.
news
- Paul Hastings Advised Oppenheimer & Co. and Citizens JMP as Joint Book Running Managers in Connection with INOVIO’s Underwritten Offering - April 17th, 2024
- Paul Hastings Advised J.P. Morgan in Connection with Leap Therapeutics’ PIPE Financing - April 11th, 2024
- Paul Hastings Advised BofA Securities in Connection with Century Therapeutics’ PIPE Financing - April 11th, 2024
- Paul Hastings Advised NervGen Pharma on its Bought Deal Offering - March 28th, 2024
- Paul Hastings advised Piper Sandler and Co. and Oppenheimer & Co. in connection with Skye Bioscence, Inc.’s PIPE - March 12th, 2024
- Paul Hastings Advised Leerink Partners and Stifel in connection with Evolus Inc.’s Underwritten Offering - March 12th, 2024
- Paul Hastings advised J.P. Morgan and Leerink Partners in connection with Lexeo Therapuetics’ PIPE - March 11th, 2024
- Paul Hastings Advised Underwriters on Humacyte’s $40 Million Public Offering - March 1st, 2024
- Paul Hastings Advised Leerink Partners on PepGen’s $80.1 Million Underwritten Offering - February 7th, 2024
- Paul Hastings Advised Piper Sandler and Oppenheimer & Co. on Skye Biosciences’ $50.25 Million PIPE Financing - January 29th, 2024
- Paul Hastings Advised Jefferies LLC on Esperion Therapeutics’ $85.1 Million Public Offering - January 19th, 2024
- Paul Hastings Advised Goldman Sachs, J.P. Morgan, TD Cowen, and Stifel on Syndax Pharmaceuticals’ $200 Million Public Offering - December 15th, 2023
- Paul Hastings Advised Jefferies and Leerink Partners on AC Immune SA’s $50 Million Common Stock Offering - December 15th, 2023
- Paul Hastings Advised BofA Securities and Goldman Sachs & Co. LLC on Arvinas’ $350 Million Private Placement - November 27th, 2023
- Paul Hastings Advised Piper Sandler on $42 Million Private Placement in Connection with Q32 Bio and Homology Medicines Merger - November 21st, 2023
- Paul Hastings Advised Underwriters on Lexeo Therapeutics’ $100 Million IPO and Listing on Nasdaq - November 3rd, 2023
- Paul Hastings Advised Placement Agents on Harpoon Therapeutics’ $150 Million Private Placement - October 27th, 2023
- Paul Hastings Advised Underwriters on CymaBay Therapeutics, Inc.’s $258.75 Million Follow-On Offering - September 19th, 2023
- Paul Hastings Adds Leading Equity Capital Markets and Life Sciences Partner - July 6th, 2023
Engagement & Publications
- Author, “How the biotech capital markets are faring in the time of COVID-19,” MedCity News, August 2020
- Co-Author, “Life Science Cos. Navigate Dicey Path To Public Markets,” Law360, April 2020